Long-term drug release from electrospun fibers for in vivo inflammation prevention in the prevention of peritendinous adhesions

详细信息    查看全文

• 作者：Changmin Hu^a ; ^b ; ^d ; ¹ ; Shen Liu^c ; ¹ ; Yang Zhang^c ; Bin Li^a ; ^b ; Huilin Yang^a ; ^b ; Cunyi Fan^c ; ^{fancunyi888@hotmail.com} ; Wenguo Cui^a ; ^b ; ^d ; ^{wgcui80@hotmail.com}
• 关键词：Electrospun composite fibers ; Long-term release ; Anti-adhesion ; Anti-inflammation
• 刊名：Acta Biomaterialia
• 出版年：2013
• 出版时间：July, 2013
• 年：2013
• 卷：9
• 期：7
• 页码：7381-7388
• 全文大小：1964 K

文摘

Physical barriers such as electrospun fibrous membranes are potentially useful in preventing peritendinous adhesions after surgery. However, inflammatory responses caused by degradation of barrier materials remain a major challenge. This study aimed to fabricate electrospun composite fibrous membranes based on drug-loaded modified mesoporous silica (MMS) and poly (l-lactic acid) (PLLA). Using a co-solvent-based electrospinning method ibuprofen (IBU)-loaded MMS was successfully and uniformly encapsulated in the PLLA fibers. The electrospun PLLA-MMS-IBU composite fibrous membranes showed significantly lower initial burst release (6 % release in the first 12 h) compared with that of electrospun PLLA-IBU fibrous membranes (46 % release in the first 12 h) in in vitro release tests. Moreover, the release from PLLA-MMS-IBU was also for significantly longer than that from PLLA-IBU (100 vs. 20 days). In animal studies both PLLA-IBU and PLLA-MMS-IBU showed improved anti-adhesion properties and anti-inflammatory effects compared with PLLA fibrous membrane alone 4 weeks after implantation. Further, animals implanted with PLLA-MMS-IBU for 8 weeks showed the lowest inflammation and best recovery compared with those implanted with PLLA-IBU and PLLA, most likely as a result of its long-term IBU release profile. Therefore, this study provides a platform technique for fabricating fibrous membranes with long-term sustained drug release characteristics which may function as a novel carrier for long-term anti-inflammation and anti-adhesion to prevent peritendinous adhesions.